Business in Brief
No major side effects for Teva after Copaxone patent loss; Mivtach Shamir opens talks with Bright Food over possible Tnuva deal, Castro profits slump and tech shares lead TASE above 1,400 points.
Mild market reaction as Teva loses Copaxone patent
Want to enjoy 'Zen' reading - with no ads and just the article? Subscribe today